MNMD

⚠️ TICKER IS DEAD. DO NOT ROUTE ORDERS TO "MNMD." MindMed rebranded to Definium Therapeutics (announced 2026-01-09); shares began trading under DFTX on 2026-01-15. Lead asset MM120 was renamed DT120; MM402 → DT402. This dossier keeps the MNMD key for pipeline continuity, but the only tradeable security is DFTX. Any execution against MNMD will fail or fill stale.

Current Thesis

This is not a momentum setup — it is a binary-catalyst lottery ticket, and the binary is ~3 weeks out. Definium (ex-MindMed) is a clinical-stage psychedelic-psychiatry name whose entire 2026 value lives in three Phase 3 readouts of DT120 (a pharmaceutically optimized, single-dose LSD orally disintegrating tablet). The first and nearest, EMERGE in major depressive disorder (149 pts, fully enrolled), reports topline in late Q2 2026 — i.e., this month/next. Stock has run from ~$20.43 (late May 2026) to ~$24.87 (2026-06-04), roughly +20% straight into the print. Buying here is buying a coin-flip under the shadow of the FDA's 2024 Lykos/MDMA rejection. The playbook does not gamble pre-data on functionally-unblinded psychedelic trials — probe-only or wait for the print to de-risk.

Bull Case

• Best-in-class, de-risked Phase 2b for the platform: a single 100µg MM120/DT120 dose drove a ~7.6-point placebo-adjusted HAM-A reduction at Week 4 in GAD, with durability through Week 12 and open-label follow-up to Week 52 (published in JAMA). One dose, multi-month effect = a genuinely differentiated commercial story vs daily SSRIs.
• FDA Breakthrough Therapy Designation for GAD (granted March 2024) — regulatory tailwind and a signal the agency took the Phase 2b seriously.
• Three shots on goal in 2026: EMERGE (MDD, late Q2), VOYAGE (GAD, ~200 pts, Q3) and PANORAMA (GAD, ~250 pts US+EU, Q3), plus DT402 Phase 2a in ASD. A single clean GAD/MDD win re-rates the whole equity.
• Funded through the catalysts: $373.4M cash/equivalents/investments as of 2026-03-31, runway into 2028, plus a $120M facility ($41M drawn). No dilution gun to the head pre-readout.
• Street is leaning bullish: consensus Strong Buy, avg PT ~$28–30, high $61 (Jones Trading); Needham named it a top 2026 pick / Conviction List (Buy, $28 PT, 2025).

Bear Case

• Functional unblinding is the entire bear thesis. Patients dosed with LSD know they tripped; placebo patients know they didn't. The FDA rejected Lykos/MAPS' MDMA-for-PTSD in August 2024 (CRL) after an adcomm voted ~9–2 / 10–1 against in June 2024, citing exactly this design flaw plus missing data and safety. That precedent hangs over every psychedelic Phase 3 readout, including EMERGE.
• MDD is a brutal endpoint: placebo response in depression trials is high and noisy; a functionally-unblinded LSD arm makes a clean MADRS separation harder to defend to regulators even if statistically significant.
• Pure binary, zero revenue. A miss on EMERGE (late Q2 2026) is a 40–70% gap-down risk overnight and a negative read-through into VOYAGE/PANORAMA odds.
• Extended into the event: +~20% in ~2 weeks pre-print is precisely the "chase into binary risk" beginner trap. The most conservative analyst (Baird) PT implies downside from here.

Setup & Price Structure

• Last (2026-06-04): ~$24.87, intraday range $23.16–$25.16. Up from ~$20.43 (late May 2026) → roughly +20–22% in two weeks, pressing toward the upper end of its recent range and into the catalyst.
• Base reference ~$19–20 (the pre-run May 2026 shelf). A loss of that shelf without a data event = the speculative bid has left.
• Structure read: this is anticipation-buying ahead of a binary, not an accelerating narrative with cluster breakout confirmation. RSI is elevated on the two-week run; "extended + no pullback" here is NOT confirmation (this is archetype 5, not 1) — it is event-premium that vaporizes on the print.
• R/R framing: pre-binary, payoff is bimodal (gap up on a hit, gap down on a miss) — not the >3:1 trend setup this book wants. Position sizing must respect that.

Catalyst Calendar (next 30 days)

• ~2026-06-25 (est., "late Q2 2026"): EMERGE Phase 3 topline — DT120 ODT 100µg in MDD, 149 pts randomized, primary = change in MADRS vs placebo. THE binary. Fully enrolled per Q1 2026 update (reported 2026-05-07).
• (Outside 30d, flag) Q3 2026: VOYAGE (GAD, HAM-A Week 12 primary, ~200 pts) and PANORAMA (GAD, ~250 pts US+EU) toplines.
• (Outside 30d) DT402 (R(-)-MDMA) Phase 2a in ASD — data expected 2026.
• No earnings in the next 30d (Q1 2026 reported 2026-05-07; Q2 ≈ early Aug). The clinical print, not the financial print, is the event.

What Would Change Our Mind

• EMERGE hits clean (statistically significant MADRS separation, functional-unblinding critique manageable, safety clean) → theme flips to ACCELERATING with de-risked data. The disciplined entry is THEN — buy the confirmed gap-and-retest at higher conviction. Data-confirmed > data-anticipated.
• EMERGE misses or is ambiguous → thesis impaired, exit/avoid; haircut VOYAGE/PANORAMA probabilities and the whole psychedelic complex.
• FDA framework signal: any agency guidance accepting psychedelic trial designs / addressing functional unblinding post-Lykos would structurally de-risk the entire space and warrant a re-rate higher even before DFTX's own data.
• Loss of the ~$19–20 base on no news → speculative bid gone, stand aside.

Correlation Notes

• Tight cluster with listed psychedelic peers: CMPS (Compass Pathways, psilocybin COMP360 in TRD — its own Phase 3 readouts are the main theme co-mover) and ATAI (atai Life Sciences). A Lykos-style negative regulatory headline hits all three together regardless of DFTX's own data.
• Low correlation to SPY / macro / rates in the near term — DFTX is a single-stock binary; on readout day it trades its own data, not the tape. That makes index hedges useless and makes sizing (not stops) the primary risk control.
• Read-through is bidirectional: an EMERGE hit lifts CMPS/ATAI; a miss tags the whole basket. Don't double-up on correlated psychedelic exposure into the same readout window.